Please try another search
N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Nigel James Theobald | 60 | 2014 | Founder, CEO & Executive Director |
David Templeton | 72 | 2017 | Executive Director & Technical Director |
Luke Sebastian Cairns | 46 | 2020 | Executive Director |
Christopher Jonathan Britten | 57 | 2019 | Independent Non-Executive Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review